Search clinical trials for: Docetaxel

Total 2012 results

NCT06060587

Not yet recruiting

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

Prostate Cancer
NCT06057610

Not yet recruiting

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

HER2-PositiveRecurrent or Metastatic Breast Cancer
NCT06046482

Not yet recruiting

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck | Head Neck
NCT06042569

Recruiting

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | HER2-Negative Breast Carcinoma
NCT06038539

Not yet recruiting

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
NCT06028737

Recruiting

Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR)

Stomach Cancer | Gastric Cancer | Gastric Adenocarcinoma | Gastrointestinal Cancer | Gastroesophageal Junction Adenocarcinoma | Advanced Gastric Adenocarcinoma | GastroEsophageal Cancer | Stomach Neoplasm | Gastric Neoplasm | Advanced Gastric Carcinoma
NCT06029127

Not yet recruiting

A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer
NCT06023875

Recruiting

Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma (NCCCNRHNSCC)

Head and Neck Squamous Cell Carcinoma | Locally Advanced Operable
NCT06012435

Not yet recruiting

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
NCT06009627

Recruiting

Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

Breast Cancer
NCT05999994

Recruiting

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer (CAMPFIRE)

Adolescent | Neoplasms | Child
NCT05983783

Recruiting

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

Chemotherapy Effect | Metastatic Prostate Cancer | Hormone Sensitive Prostate Cancer
NCT05978648

Not yet recruiting

Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy (SMA-BC-002)

Breast Neoplasms
NCT05960955

Not yet recruiting

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05943795

Recruiting

A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Squamous Cell Carcinoma of Lung | Non-small Cell Lung Adenocarcinoma
NCT05929768

Recruiting

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Early Stage Triple-Negative Breast Carcinoma
NCT05922345

Recruiting

Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.

Non-small Cell Lung Cancer
NCT05919537

Recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With NRG1 Gene Fusion Advanced Solid Tumors

Pancreatic Cancer | Non-Small Cell Lung Cancer | Metastatic Solid Tumor | Locally Advanced Solid Tumor
NCT05914753

Not yet recruiting

Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer

Breast Cancer | Chemotherapy Effect
NCT05910827

Recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
NCT05910034

Not yet recruiting

Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC

Advanced Non-Small Cell Lung Cancer
NCT05904379

Recruiting

AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer

Advanced Non-small-cell Lung Cancer
NCT05901428

Recruiting

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Hormone Receptor Positive HER-2 Negative Breast Cancer
NCT05900206

Not yet recruiting

Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer (ARIADNE)

Breast Cancer
NCT05883852

Recruiting

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

HER2 Positive Early Breast Cancer
NCT05878028

Recruiting

L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC

Non-small Cell Lung Cancer
NCT05863325

Not yet recruiting

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT05848011

Recruiting

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Recurrent | Immunotherapy | Androgen-Independent Prostatic Cancer | Androgen-Resistant Prostatic Cancer | Hormone Refractory Prostatic Cancer | Immune Checkpoint Inhibitor | Androgen-Independent Prostatic Neoplasms | Androgen-Insensitive Prostatic Cance | Inhibitory Checkpoint Molecule
NCT05836584

Recruiting

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Gastric Adenocarcinoma | Gastric Carcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Gastroesophageal Junction Adenocarcinoma | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
NCT05838066

Not yet recruiting

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
NCT05834348

Not yet recruiting

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. (DELINOR)

Non-Small Cell Lung Cancer
NCT05816499

Recruiting

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) (AK104IIT018)

NSCLC Stage IV | NSCLC Stage IIIB | NSCLC Stage IIIC
NCT05813015

Recruiting

Study of Comparing of With and Without Sequential Therapy of S-1

Chemotherapy Effect | Locally Advanced Gastric Adenocarcinoma
NCT05800587

Recruiting

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Lung Cancer | Non Small Cell Lung Cancer | Small-cell Lung Cancer
NCT05800054

Recruiting

Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer

Esophageal Neoplasms | Adverse Drug Event
NCT05798793

Not yet recruiting

Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma (NEOPCOSCC)

Oral Squamous Cell Carcinoma
NCT05777278

Not yet recruiting

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

Non-small Cell Lung Cancer
NCT05769725

Recruiting

A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer

Serplulimab,Gastric Cancer, Adjuvant Therapy
NCT05762536

Not yet recruiting

Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC (DAROTAXEL)

Metastatic Castration-resistant Prostate Cancer
NCT05754853

Recruiting

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Advanced or Metastatic Urothelium Cancer
NCT05753306

Recruiting

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Metastatic Malignant Neoplasm in the Peritoneum
NCT05733689

Not yet recruiting

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Gastroesophageal Adenocarcinoma
NCT05733351

Recruiting

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Castration-Sensitive Prostate Carcinoma
NCT05727410

Recruiting

Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma

High-grade Salivary Gland Carcinoma
NCT05726370

Not yet recruiting

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Resectable Head and Neck Squamous Cell Carcinoma
NCT05720026

Recruiting

Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer

HER2-positive Breast Cancer
NCT05715931

Recruiting

Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

HER2-positive Gastric Cancer | Adenocarcinoma of the Stomach | Adenocarcinoma of Esophagogastric Junction
NCT05713578

Recruiting

Efficacy and Safety of Apantamide Combined With Docetaxel and ADT vs. Apantamide Combined With ADT in Patients With High Tumor Burden mHSPC: a Multicenter and Prospective Cohort Study

Cohort Studies
NCT05714553

Recruiting

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Advanced Cancer | Head and Neck Squamous Cell Carcinoma | Endometrial Carcinoma
NCT05712356

Recruiting

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (BOLSTER)

Head and Neck Cancer | Esophageal Cancer | Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Gallbladder Carcinoma | Gallbladder Cancer | Extrahepatic Cholangiocarcinoma | Advanced Head and Neck Squamous Cell Carcinoma

X